Author

Pangsibo Shen

Observed name: Shen, Pangsibo

Institution: Analysis Group (United States)

Observed institution: Analysis Group (United States)

OpenAlex ID: A5111350112

Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir

2025 · Andrew P Beyer, Pamela A Moise, et al. · World Journal of Transplantation · 3

Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A SEER-Medicare study.

2025 · Yair Lotan, Rituparna Bhattacharya, et al. · Journal of Clinical Oncology · 2

MPN-529 Real-World Clinical Outcomes in Patients With Myelofibrosis With and Without Baseline Anemia in the Mass General Brigham Integrated Delivery Network

2024 · Gabriela Hobbs, Nicole Niehoff, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Real-World Clinical Outcomes in Patients With Myelofibrosis With and Without Baseline Anemia in the Mass General Brigham Integrated Delivery Network

2024 · Gabriela Hobbs, Nicole Niehoff, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Real-World Clinical Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin: A SEER-Medicare Analysis

2026 · Yair Lotan, Monika Raut, et al. · Clinical Genitourinary Cancer

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( SMILE )

2026 · Aleksandrina Ruseva, Wojciech Michalak, et al. · Diabetes Obesity and Metabolism

Psychosocial factors, guideline-directed medical therapy, and healthcare resource use among patients newly diagnosed with heart failure in the United States

2026 · Stephen J. Greene, Vishal Bali, et al. · American Heart Journal Plus Cardiology Research and Practice

Author response for "Semaglutide 2.4 mg Cardiometabolic Long-term Effects in Patients with Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE)"

2026 · Aleksandrina Ruseva, Wojciech Michalak, et al.

Author response for "Semaglutide 2.4 mg Cardiometabolic Long-term Effects in Patients with Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE)"

2026 · Aleksandrina Ruseva, Wojciech Michalak, et al.

Abstract 4368652: Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg

2025 · Aleksandrina Ruseva, Matthew Bassan, et al. · Circulation

P1 Economic Burden of Recurrence among Patients with High-Risk Non-Muscle-Invasive Bladder Cancer who Received Bacillus Calmette-Guérin in the United States: A SEER-Medicare Study

2025 · Rituparna Bhattacharya, Honghao Fang, et al. · Value in Health

The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database

2024 · Ruixuan Jiang, Travis Wang, et al. · Journal of Medical Economics

Works count: 13

Citation count: 7

H-index: 2

I10-index: